On May 10, 2022 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") reported that its management team will participate in the following upcoming investor conferences and events (Press release, Calliditas Therapeutics, MAY 10, 2022, View Source [SID1234614045]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 8th Annual LSX World Congress on May 10-11, 2022 in London, United Kingdom
The ABGSC Life Science Summit on May 18–19, 2022, in Stockholm, Sweden.
H.C. Wainwright Hybrid Global Investment Conference on May 23-26, 2022.
Jefferies Healthcare Conference on June 8-10, 2022 in New York City, USA.
Citi European Healthcare Conference on June 14–16, 2022 in London, United Kingdom
At the LSX World Congress, Calliditas Chief Executive Officer Renée Aguiar-Lucander, Chief Financial Officer Fredrik Johansson and President of North America, Andrew Udell will speak in three separate panel discussions focused on global commercial strategy, IPO listings, and product launching, respectively.

Renee Aguiar-Lucander will present at the ABGSC Life Science Summit on May 19th at 11:30am to 12pm CET.

Management will be presenting and will host one-on-one investor meetings at the other three conferences. To schedule a one-on-one meeting with Calliditas, please contact your representative at H.C Wainwright, Jefferies, or Citi.

The information was sent for publication, through the agency of the contact persons set out above, on May 10, 2022 at 8:30 a.m. CET.

On May 10, 2022 Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that the Company’s senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY (Press release, Karyopharm, MAY 10, 2022, View Source [SID1234614025]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay for 90 days following the event.

On May 10, 2022 CTI BioPharma Corp. (Nasdaq: CTIC) reported one poster presentation from the Company’s pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021 (Press release, CTI BioPharma, MAY 10, 2022, View Source [SID1234614024]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of the poster presentation are as follows:

Abstract Title: Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF)
Abstract Number: 7058
Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date: Saturday, June 4, 2022
Presentation Time: 8:00 – 11:00 a.m. CDT (11:00 a.m. – 2:00 p.m. ET)
Presenter: Dr. Naveen Pemmaraju

About Pacritinib
Pacritinib is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Myelofibrosis is often associated with dysregulated JAK2 signaling. Pacritinib has higher inhibitory activity for JAK2 over other family members, JAK3 and TYK2. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.

On May 10, 2022 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference, which is taking place May 17-18, 2022 at the InterContinental New York Barclay in New York, NY (Press release, Oncolytics Biotech, MAY 10, 2022, View Source [SID1234614023]). Additional details on the fireside chat can be found below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, contact your RBC representative or email [email protected].

A live webcast of the Company’s presentation will also be available on the Investor Relations page of Oncolytics’ website (LINK) and will be archived until August 15, 2022.

On May 10, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, reported that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 9:30 a.m. EST in New York (Press release, IGM Biosciences, MAY 10, 2022, View Source [SID1234614022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.